263 related articles for article (PubMed ID: 30796092)
1. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes.
Fox JM; Roy V; Gunn BM; Huang L; Edeling MA; Mack M; Fremont DH; Doranz BJ; Johnson S; Alter G; Diamond MS
Sci Immunol; 2019 Feb; 4(32):. PubMed ID: 30796092
[TBL] [Abstract][Full Text] [Related]
2. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.
Pal P; Dowd KA; Brien JD; Edeling MA; Gorlatov S; Johnson S; Lee I; Akahata W; Nabel GJ; Richter MK; Smit JM; Fremont DH; Pierson TC; Heise MT; Diamond MS
PLoS Pathog; 2013; 9(4):e1003312. PubMed ID: 23637602
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography.
Fox JM; Roy V; Gunn BM; Bolton GR; Fremont DH; Alter G; Diamond MS; Boesch AW
Front Immunol; 2023; 14():1153108. PubMed ID: 37251375
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
[TBL] [Abstract][Full Text] [Related]
5. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE
Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672
[TBL] [Abstract][Full Text] [Related]
6. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
7. Divergent Requirement of Fc-Fcγ Receptor Interactions for
Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
Clayton AM
J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.
Quiroz JA; Malonis RJ; Thackray LB; Cohen CA; Pallesen J; Jangra RK; Brown RS; Hofmann D; Holtsberg FW; Shulenin S; Nyakatura EK; Durnell LA; Rayannavar V; Daily JP; Ward AB; Aman MJ; Dye JM; Chandran K; Diamond MS; Kielian M; Lai JR
PLoS Pathog; 2019 Nov; 15(11):e1008061. PubMed ID: 31697791
[TBL] [Abstract][Full Text] [Related]
10. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
Winkler ES; Gilchuk P; Yu J; Bailey AL; Chen RE; Chong Z; Zost SJ; Jang H; Huang Y; Allen JD; Case JB; Sutton RE; Carnahan RH; Darling TL; Boon ACM; Mack M; Head RD; Ross TM; Crowe JE; Diamond MS
Cell; 2021 Apr; 184(7):1804-1820.e16. PubMed ID: 33691139
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of Chikungunya virus inhibition by monoclonal antibodies.
Zhou QF; Fox JM; Earnest JT; Ng TS; Kim AS; Fibriansah G; Kostyuchenko VA; Shi J; Shu B; Diamond MS; Lok SM
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27637-27645. PubMed ID: 33087569
[TBL] [Abstract][Full Text] [Related]
12. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
[TBL] [Abstract][Full Text] [Related]
13. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.
Smith SA; Silva LA; Fox JM; Flyak AI; Kose N; Sapparapu G; Khomandiak S; Ashbrook AW; Kahle KM; Fong RH; Swayne S; Doranz BJ; McGee CE; Heise MT; Pal P; Brien JD; Austin SK; Diamond MS; Dermody TS; Crowe JE
Cell Host Microbe; 2015 Jul; 18(1):86-95. PubMed ID: 26159721
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
[TBL] [Abstract][Full Text] [Related]
15. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
[TBL] [Abstract][Full Text] [Related]
16. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
Weber C; Büchner SM; Schnierle BS
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
[TBL] [Abstract][Full Text] [Related]
17. Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.
Keeler SP; Fox JM
Viruses; 2021 May; 13(6):. PubMed ID: 34072720
[TBL] [Abstract][Full Text] [Related]
18. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.
Vogt MR; Dowd KA; Engle M; Tesh RB; Johnson S; Pierson TC; Diamond MS
J Virol; 2011 Nov; 85(22):11567-80. PubMed ID: 21917960
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity.
Earnest JT; Basore K; Roy V; Bailey AL; Wang D; Alter G; Fremont DH; Diamond MS
J Exp Med; 2019 Oct; 216(10):2282-2301. PubMed ID: 31337735
[TBL] [Abstract][Full Text] [Related]
20. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.
Malonis RJ; Earnest JT; Kim AS; Angeliadis M; Holtsberg FW; Aman MJ; Jangra RK; Chandran K; Daily JP; Diamond MS; Kielian M; Lai JR
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
